EKTA-B Stock Analysis: Elekta (publ) | ST
Medical Devices | ST, Sweden | Market Cap: 19.715m SEK | 12M Return: 16.9% | SE0000163628 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 58.9M
EPS Trend: -91.6%
Qual. Beats: 0
Rev. Trend: -87.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Elekta AB (publ) is a Swedish medical technology company that develops clinical solutions for the treatment of cancer and brain disorders. Founded in 1972 and headquartered in Stockholm, the company sells its products across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
Its product portfolio centers on radiation-based therapies. The linear accelerator line includes systems such as Elekta Unity (MR-guided), Elekta Evo (CT-Linac), Versa HD, Harmony, and Infinity. The company also offers stereotactic radiosurgery through its Gamma Knife–based Esprit system, a range of brachytherapy products (including Studio, Oncentra Brachy, Venezia, Flexitron, Geneva, and the Xoft Axxent electronic brachytherapy system), the Leksell Vantage stereotactic neurosurgery system, and the Elekta Kaiku platform for personalized cancer care. Brachytherapy is a form of internal radiation therapy in which a radioactive source is placed directly at or near the tumor site.
Elekta complements its hardware with the Elekta Care services suite, which covers clinical and professional support, training, customer communities, and partner self-service resources. The company also supplies veterinary radiation therapy solutions. It is listed on the Stockholm Stock Exchange under the ticker EKTA-B and is classified within the health care sector, specifically the life sciences tools and services sub-industry.
- Linear accelerator order growth drives radiotherapy segment revenue
- Africa and Asia Pacific emerging market expansion offsets mature region softness
- Brachytherapy and software attach margins expand service recurring revenue
- US reimbursement and hospital capital budgets limit elective radiation equipment purchases
| Net Income: -362.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: -11.77% < 20% (prev 3.88%; Δ -15.65% < -1%) |
| CFO/TA 0.10 > 3% & CFO 2.55b > Net Income -362.0m |
| Net Debt (5.52b) to EBITDA (1.76b): 3.14 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (382.1m) vs 12m ago 0.02% < -2% |
| Gross Margin: 38.62% > 18% (prev 37.40%; Δ 1.21% > 0.5%) |
| Asset Turnover: 59.49% > 50% (prev 61.19%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: 3.05 > 6 (EBIT TTM 1.05b / Interest Expense TTM 344.0m) |
| A: -0.07 (Total Current Assets 12.4b - Total Current Liabilities 14.4b) / Total Assets 26.7b |
| B: 0.20 (Retained Earnings 5.21b / Total Assets 26.7b) |
| C: 0.04 (EBIT TTM 1.05b / Avg Total Assets 27.9b) |
| D: 0.40 (Book Value of Equity 7.56b / Total Liabilities 19.1b) |
| Altman-Z'' = 0.83 = B |
| DSRI: 0.93 (Receivables 6.63b/7.65b, Revenue 16.6b/17.8b) |
| GMI: 0.97 (GM 37.40% / 38.62%) |
| AQI: 1.00 (AQ_t 0.47 / AQ_t-1 0.48) |
| SGI: 0.93 (Revenue 16.6b / 17.8b) |
| TATA: -0.11 (NI -362.0m - CFO 2.55b) / TA 26.7b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at SEK 54.45 with a total of 1,087,135 shares traded. Over the past week, the price has changed by +5.52%, over one month by +8.79%, over three months by +9.56% and over the past year by +16.93%.
Current recommended Stop Loss: 52.10 (which is 4.3% or 1.7 ATR below the current price).
Elekta (publ) has no consensus analysts rating.
P/E Forward = 19.2308
P/S = 1.1871
P/B = 2.627
P/EG = 0.3807
Revenue TTM = 16.6b SEK
EBIT TTM = 1.05b SEK
EBITDA TTM = 1.76b SEK
Long Term Debt = 3.38b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.71b SEK (from shortTermDebt, last quarter)
Debt = 7.83b SEK (from shortLongTermDebtTotal, last quarter) + Leases 997.0m
Net Debt = 5.52b SEK (calculated: Debt 7.83b - CCE 2.31b)
Enterprise Value = 25.2b SEK (19.7b + Debt 7.83b - CCE 2.31b)
Interest Coverage Ratio = 3.05 (Ebit TTM 1.05b / Interest Expense TTM 344.0m)
EV/FCF = 10.36x (Enterprise Value 25.2b / FCF TTM 2.44b)
FCF Yield = 9.65% (FCF TTM 2.44b / Enterprise Value 25.2b)
FCF Margin = 14.66% (FCF TTM 2.44b / Revenue TTM 16.6b)
Net Margin = -2.18% (Net Income TTM -362.0m / Revenue TTM 16.6b)
Gross Margin = 38.62% ((Revenue TTM 16.6b - Cost of Revenue TTM 10.2b) / Revenue TTM)
Gross Margin QoQ = 42.56% (prev 39.52%)
Tobins Q-Ratio = 0.95 (Enterprise Value 25.2b / Total Assets 26.7b)
Interest Expense / Debt = 4.40% (Interest Expense 344.0m / Debt 7.83b)
Taxrate = 23.01% (78.0m / 339.0m)
NOPAT = 806.9m (EBIT 1.05b * (1 - 23.01%))
Current Ratio = 0.86 (Total Current Assets 12.4b / Total Current Liabilities 14.4b)
Debt / Equity = 1.03 (Debt 7.83b / totalStockholderEquity, last quarter 7.56b)
Debt / EBITDA = 3.14 (Net Debt 5.52b / EBITDA 1.76b)
Debt / FCF = 2.27 (Net Debt 5.52b / FCF TTM 2.44b)
Total Stockholder Equity = 7.77b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.30% (Net Income -362.0m / Total Assets 26.7b)
RoE = -4.66% (Net Income TTM -362.0m / Total Stockholder Equity 7.77b)
RoCE = 9.39% (EBIT 1.05b / Capital Employed (Equity 7.77b + L.T.Debt 3.38b))
RoIC = 5.69% (NOPAT 806.9m / Invested Capital 14.2b)
WACC = 6.99% (E(19.7b)/V(27.5b) * Re(8.42%) + D(7.83b)/V(27.5b) * Rd(4.40%) * (1-Tc(0.23)))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 45.50 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈2.10b ; Y1≈2.40b ; Y5≈3.53b
[DCF] Fair Price = 129.8 (EV 53.2b - Net Debt 5.52b = Equity 47.7b / Shares 367.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.63 | EPS CAGR: -12.48% | SUE: 0.54 | # QB: 0
Revenue Correlation: -87.08 | Revenue CAGR: -3.03% | SUE: -0.72 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.75 | Chg30d=-8.90% | Revisions=-29% | Analysts=6
EPS next Quarter (2027-01-31): EPS=1.07 | Chg30d=-5.63% | Revisions=-38% | Analysts=6
EPS current Year (2027-04-30): EPS=3.91 | Chg30d=+1.19% | Revisions=+73% | GrowthEPS=+61.0% | GrowthRev=+3.1%
EPS next Year (2028-04-30): EPS=4.25 | Chg30d=+0.29% | Revisions=+36% | GrowthEPS=+8.6% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +25% (up=16, down=9)